Victor Grifols Roura decides to step down as president; Grifols Appoints Private Equity Veteran Steven F. Mayer as Executive Chairman

  • Victor Grifols Roura, who dedicated 50 years to building Grifols in leadership positions including CEO for 30 years, is retiring as Non-Executive Chairman and appointed Honorary Chairman in recognition of his many contributions
  • Steve F. Mayer, former co-head of Global Private Equity and chairman of the investment committee of a private investment firm Cerberus capital management, L.P., with more than 10 years as Griffols independent member of the board of directors, is appointed executive chairman
  • The changes further reflect the board’s focus on strategic objectives, operational excellence and deleveraging balance sheet

Barcelona, ​​Spain, October 3, 2022 /PRNewswire/ — Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ:GRFS) today announced changes to its leadership team, appointing Mr. Steven F. Mayer as Executive Chairman while Mr. Victor Grifols Roura retired as Chairman and was appointed Honorary Chairman. Both changes take effect immediately.

These unanimously approved appointments demonstrate the Board’s commitment to strengthening Grifols’ leadership; accelerate the execution of the company’s strategic plan; continue to focus on operational excellence; and increase value for all shareholders, with a focus on reducing debt levels and improving the company’s cash profile.

“I have spent most of my adult life actively leading Grifols, and with the company fundamentally sound and in the hands of strong leadership, it was time for me to retire. It has been an honor to chair Grifols Board of Directors and managing the business for so long. I have known Steven since he joined our Board of Directors when we acquired Talecris in 2011 and I know that his experience, insights, skills, in-depth knowledge and significant capital markets expertise will be invaluable assets to our management team as he helps steer Grifols forward.” said Mr. Victor Grifols Roura, now Honorary Chairman of the Grifols Board of Directors.

“It is a privilege to follow Victor as Chairman of this important global healthcare company, and I look forward to taking on this role at such an important time for Grifols. Although Victor’s shoes are impossible to fulfill, I am delighted to work alongside the Board of Directors, Co-CEOs and the entire management team, using my expertise to help them achieve the company’s strategic objectives and focus on the operational excellence; sustainable revenue, profitability and cash flow growth; and strengthening the company’s balance sheet. It is equally important to me to ensure that the core values ​​of integrity, respect , inclusion and sustainability of the company that Victor has established and that Victor has always adhered to, as well as his commitment to the health and well-being of patients around the world, will continue to guide the company and his entire team. go forward “, said Mr. Steven F. Mayernow Executive Chairman of the Board of Grifols.

Mr. Mayer has extensive healthcare knowledge and experience and is well versed in the plasma-derived protein therapeutics industry, having led the team that acquired and spun off Talecris Biotherapeutics from Bayer Healthcare and subsequently grew revenue and the company’s employee base and significantly improved its profitability and cash flow until its merger with Grifols in 2011, when he joined the Grifols Board of Directors. In addition to the board of Grifols, he has served on the boards or equivalent bodies of over 30 other public and private companies in a variety of industries. Prior to his retirement in 2018 from Cerberus, which today manages approximately $60 billion of Capital, as Senior Managing Director, Co-Head of Global Private Equity and Chairman of its Investment Committee, Mr. Mayer focused on opportunities to improve the competitiveness and value of portfolio companies through operational planning and execution as well as strategic initiatives and financial discipline.

In parallel, Mr. Victor Grifols Roura will continue to be a member of the Grifols Board of Directors and a valuable resource as “Director Owner” and has also been named Honorary Chairman due to his invaluable contributions, leadership unwavering and extraordinary dedication to the company.

“It is impossible to say enough about what Victor has meant for Grifols and its entire ecosystem, and in particular for the patients whose lives the company has improved, all over the world” said Carina SzpilkaLead Independent Director of the Grifols Board of Directors. “Victor was the man responsible for taking Grifols from a small, predominantly Spanish company 20 years ago and, through his vision, passion, expertise and leadership, transforming it into the global healthcare leader in billions of dollars he has become today. The entire Board of Directors is grateful to Victor and committed to honoring his legacy by capitalizing on the many strengths of the company and the momentum of the industry. while overseeing the management team’s continued execution of its strategic plan.We know that Steven’s appointment as Executive Chairman will facilitate the achievement of these goals.He has the full support of all of the board members of administration and our commitment to strong governance practices.”

Co-CEO of Grifols, Victor Grifols Deu and Raimon Grifols Rouraalso commented on the nominations. “Victor has always inspired us and served as a role model as we have led the business over the past five years, which included the challenges posed by the coronavirus pandemic from which the business is rapidly recovering. We have also long looked up to Steven both for what he and his team have accomplished at Talecris and for his insights and contributions to our Board of Directors, and we are delighted to introduce him to our extended team of world-class leaders and employees. , and working with him to create value for all a continued laser focus on our strategic plan, operational execution and deleveraging our balance sheet.”

About Steven F. Mayer

Steven F. Mayer has been a director of Grifols, SA since January 2011. He is currently Chairman and CEO of Iron Horse Acquisition Corp. and Dedication Capital, LLC, private investment firms he founded. From 2002 to 2018, he held various executive positions at Cerberus Capital Management, LP and Cerberus California, LLC, affiliated private investment firms, culminating as Senior Managing Director, Co-Head of Global Private Equity and Chairman of Cerberus Investment Committee. He began his private equity career as a principal at Apollo Advisors, LP in 1992.

He holds a Bachelor of Arts, cum laude, from princeton university and a Juris Doctor degree, magna cum laude, from Harvard Law School and has taught courses at these two institutions as well as at LUISS, a university in Rome.

Mr. Mayer has served on the board of directors or equivalent of a large number of corporations in a wide variety of industries in the United States and Europe. He is currently a member of the supervisory board of Syntellix, AG and a director of PrettyParty, LLC and 9Squared, LLC.

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its three main business units – Biopharma, Diagnostics and Bio Supplies – develop, produce and market innovative solutions and services that are sold in more than 110 countries.

Pioneers in the plasma industry, Grifols operates a growing network of donation centers around the world. It transforms collected plasma into essential drugs to treat rare, chronic and sometimes fatal diseases. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to improve safety, from donation to transfusion. Additionally, the company provides tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver specialized medical care.

Grifols, which has more than 27,000 employees in more than 30 countries, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2021, the economic impact of Grifols in its main countries of operation was €7.7 billion. The company also generated 141,500 jobs, including indirect and induced.

The company’s Class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE: GRF). Grifols Class B non-voting shares are listed on the Mercado Continuo (MCE: GRF.P) and on the US NASDAQ through ADR (NASDAQ: GRFS). For more information, please visit


Facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and phrases such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, insofar as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect management’s assumptions, assumptions, expectations and forecasts at the time of writing, and are subject to a number of factors that mean actual results may be materially different. The future results of the Grifols group could be affected by events related to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competing products on the market, or changes in the regulatory framework of the markets in which it operates, among others. At the date of writing this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, SA undertakes no obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances after the date of this report, except as expressly required by the applicable legislation. This document does not constitute an offer or invitation to purchase or subscribe for shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of October 23, approving the recast text of the Securities Market Law movables; Royal Decree-Law 5/2005, of March 11 and/or Royal decree 1310/2005, of November 4, and any regulation developing this legislation. Furthermore, this document does not constitute an offer to buy, sell or exchange, nor a request for an offer to buy, sell or exchange securities, nor a request to vote or approve in any other jurisdiction. The information contained in this document has not been verified or examined by the external auditors of the Grifols group.

SOURCE Grifols


About Author

Comments are closed.